Literature DB >> 31584620

CRISPR/Cas9 gene-editing strategies in cardiovascular cells.

Eva Vermersch1, Charlène Jouve1, Jean-Sébastien Hulot1,2.   

Abstract

Cardiovascular diseases are among the main causes of morbidity and mortality in Western countries and considered as a leading public health issue. Therefore, there is a strong need for new disease models to support the development of novel therapeutics approaches. The successive improvement of genome editing tools with zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and more recently with clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (Cas9) has enabled the generation of genetically modified cells and organisms with much greater efficiency and precision than before. The simplicity of CRISPR/Cas9 technology made it especially suited for different studies, both in vitro and in vivo, and has been used in multiple studies evaluating gene functions, disease modelling, transcriptional regulation, and testing of novel therapeutic approaches. Notably, with the parallel development of human induced pluripotent stem cells (hiPSCs), the generation of knock-out and knock-in human cell lines significantly increased our understanding of mutation impacts and physiopathological mechanisms within the cardiovascular domain. Here, we review the recent development of CRISPR-Cas9 genome editing, the alternative tools, the available strategies to conduct genome editing in cardiovascular cells with a focus on its use for correcting mutations in vitro and in vivo both in germ and somatic cells. We will also highlight that, despite its potential, CRISPR/Cas9 technology comes with important technical and ethical limitations. The development of CRISPR/Cas9 genome editing for cardiovascular diseases indeed requires to develop a specific strategy in order to optimize the design of the genome editing tools, the manipulation of DNA repair mechanisms, the packaging and delivery of the tools to the studied organism, and the assessment of their efficiency and safety. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  CRISPR/Cas9; Cardiomyopathy; Disease modelling; Genetics; Genome editing

Year:  2020        PMID: 31584620     DOI: 10.1093/cvr/cvz250

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  13 in total

Review 1.  Signaling cascades in the failing heart and emerging therapeutic strategies.

Authors:  Xin He; Tailai Du; Tianxin Long; Xinxue Liao; Yugang Dong; Zhan-Peng Huang
Journal:  Signal Transduct Target Ther       Date:  2022-04-23

Review 2.  Deciphering Common Long QT Syndrome Using CRISPR/Cas9 in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Authors:  Yongfei Song; Zequn Zheng; Jiangfang Lian
Journal:  Front Cardiovasc Med       Date:  2022-05-13

3.  Special issue on recent progress with hPSC-derived cardiovascular cells for organoids, engineered myocardium, drug discovery, disease models, and therapy.

Authors:  Kenneth R Boheler; Albano C Meli; Huang-Tian Yang
Journal:  Pflugers Arch       Date:  2021-06-16       Impact factor: 3.657

4.  Application of CRISPR-Cas9 gene editing for congenital heart disease.

Authors:  Heeyoung Seok; Rui Deng; Douglas B Cowan; Da-Zhi Wang
Journal:  Clin Exp Pediatr       Date:  2021-03-02

Review 5.  CRISPR-Cas and Its Wide-Ranging Applications: From Human Genome Editing to Environmental Implications, Technical Limitations, Hazards and Bioethical Issues.

Authors:  Roberto Piergentili; Alessandro Del Rio; Fabrizio Signore; Federica Umani Ronchi; Enrico Marinelli; Simona Zaami
Journal:  Cells       Date:  2021-04-21       Impact factor: 7.666

Review 6.  Recent Advances in CRISPR/Cas9-Based Genome Editing Tools for Cardiac Diseases.

Authors:  Juliët Schreurs; Claudia Sacchetto; Robin M W Colpaert; Libero Vitiello; Alessandra Rampazzo; Martina Calore
Journal:  Int J Mol Sci       Date:  2021-10-12       Impact factor: 5.923

Review 7.  Strategies for High-Efficiency Mutation Using the CRISPR/Cas System.

Authors:  Shuying Feng; Zilong Wang; Aifang Li; Xin Xie; Junjie Liu; Shuxuan Li; Yalan Li; Baiyan Wang; Lina Hu; Lianhe Yang; Tao Guo
Journal:  Front Cell Dev Biol       Date:  2022-02-07

Review 8.  Cardiac Organoids to Model and Heal Heart Failure and Cardiomyopathies.

Authors:  Magali Seguret; Eva Vermersch; Charlène Jouve; Jean-Sébastien Hulot
Journal:  Biomedicines       Date:  2021-05-18

Review 9.  Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing.

Authors:  Dito Anurogo; Nova Yuli Prasetyo Budi; Mai-Huong Thi Ngo; Yen-Hua Huang; Jeanne Adiwinata Pawitan
Journal:  Int J Mol Sci       Date:  2021-06-10       Impact factor: 5.923

Review 10.  Chronic Cardiotoxicity Assays Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs).

Authors:  Akshay Narkar; James M Willard; Ksenia Blinova
Journal:  Int J Mol Sci       Date:  2022-03-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.